BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36293034)

  • 21. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia.
    Minagawa H; Hashii Y; Nakajima H; Fujiki F; Morimoto S; Nakata J; Shirakawa T; Katayama T; Tsuboi A; Ozono K
    BMC Cancer; 2023 Feb; 23(1):167. PubMed ID: 36803483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ.
    Murao A; Oka Y; Tsuboi A; Elisseeva OA; Tanaka-Harada Y; Fujiki F; Nakajima H; Nishida S; Hosen N; Shirakata T; Hashimoto N; Myoui A; Ueda T; Takeda Y; Osaki T; Enomoto T; Yoshikawa H; Kimura T; Oji Y; Kawase I; Sugiyama H
    Cancer Sci; 2010 Apr; 101(4):848-54. PubMed ID: 20136847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of EpCAM-positive microparticles in pleural fluid: A new approach to mini-invasively identify patients with malignant pleural effusions.
    Roca E; Lacroix R; Judicone C; Laroumagne S; Robert S; Cointe S; Muller A; Kaspi E; Roll P; Brisson AR; Tantucci C; Astoul P; Dignat-George F
    Oncotarget; 2016 Jan; 7(3):3357-66. PubMed ID: 26689993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer.
    Shibaki R; Murakami S; Shinno Y; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Motoi N; Yamamoto N; Ohe Y
    Thorac Cancer; 2019 Apr; 10(4):815-822. PubMed ID: 30762312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus.
    Caraballo Cortés K; Osuch S; Perlejewski K; Pawełczyk A; Kaźmierczak J; Janiak M; Jabłońska J; Nazzal K; Stelmaszczyk-Emmel A; Berak H; Bukowska-Ośko I; Paciorek M; Laskus T; Radkowski M
    J Viral Hepat; 2019 Aug; 26(8):942-950. PubMed ID: 30972915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.
    Scherpereel A; Grigoriu BD; Noppen M; Gey T; Chahine B; Baldacci S; Trauet J; Copin MC; Dessaint JP; Porte H; Labalette M
    BMC Cancer; 2013 Jul; 13():324. PubMed ID: 23816056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
    Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
    J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor antigen-specific CD8
    Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
    Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of Malignant Pleural Effusion Resident CD8
    Dhupar R; Okusanya OT; Eisenberg SH; Monaco SE; Ruffin AT; Liu D; Luketich JD; Kammula US; Bruno TC; Lotze MT; Soloff AC
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the tumour microenvironment phenotypes in malignant tissues and pleural effusion from advanced osteoblastic osteosarcoma patients.
    Zhang Z; Ji W; Huang J; Zhang Y; Zhou Y; Zhang J; Dong Y; Yuan T; Yang Q; Ding X; Tang L; Li H; Yin J; Wang Y; Ji T; Fei J; Zhang B; Chen P; Hu H
    Clin Transl Med; 2022 Nov; 12(11):e1072. PubMed ID: 36305631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
    Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
    BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-26 promotes the pathogenesis of malignant pleural effusion by enhancing CD4
    Niu Y; Ye L; Peng W; Wang Z; Wei X; Wang X; Li Y; Zhang S; Xiang X; Zhou Q
    J Leukoc Biol; 2021 Jul; 110(1):39-52. PubMed ID: 33847412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer.
    Nishida S; Morimoto S; Oji Y; Morita S; Shirakata T; Enomoto T; Tsuboi A; Ueda Y; Yoshino K; Shouq A; Kanegae M; Ohno S; Fujiki F; Nakajima H; Nakae Y; Nakata J; Hosen N; Kumanogoh A; Oka Y; Kimura T; Sugiyama H
    J Immunother; 2022 Jan; 45(1):56-66. PubMed ID: 34874330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineered lactococcus lactis intrapleural therapy promotes regression of malignant pleural effusion by enhancing antitumor immunity.
    Fan Y; Chen A; Zhu J; Liu R; Mei Y; Li L; Sha X; Wang X; Ren W; Wang L; Liu B
    Cancer Lett; 2024 Apr; 588():216777. PubMed ID: 38432582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.
    Fucikova J; Rakova J; Hensler M; Kasikova L; Belicova L; Hladikova K; Truxova I; Skapa P; Laco J; Pecen L; Praznovec I; Halaska MJ; Brtnicky T; Kodet R; Fialova A; Pineau J; Gey A; Tartour E; Ryska A; Galluzzi L; Spisek R
    Clin Cancer Res; 2019 Aug; 25(15):4820-4831. PubMed ID: 31076549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Splenic CD4
    Huang N; Zhou R; Chen H; Zhang S; Li J; Wei W; Sun J; Ren S; Li B; Deng H; Yang J; Ji F; Li Z
    Int J Immunopathol Pharmacol; 2021; 35():20587384211061051. PubMed ID: 34930041
    [No Abstract]   [Full Text] [Related]  

  • 38. Early transient suppression of immune checkpoint proteins T-cell immunoglobulin mucin-3 and programmed cell death-1 in peripheral blood lymphocytes after blastocyst transfer is associated with successful implantation.
    Zhang T; Zhu W; Zhao Y; Cheung WC; Liu Y; Chen X; Du Y; Leung KT; Chan YL; Wang CC; Laird S; Li TC
    Fertil Steril; 2020 Aug; 114(2):426-435. PubMed ID: 32199622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.
    Fourcade J; Sun Z; Pagliano O; Chauvin JM; Sander C; Janjic B; Tarhini AA; Tawbi HA; Kirkwood JM; Moschos S; Wang H; Guillaume P; Luescher IF; Krieg A; Anderson AC; Kuchroo VK; Zarour HM
    Cancer Res; 2014 Feb; 74(4):1045-55. PubMed ID: 24343228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.
    Yokota C; Kagawa N; Takano K; Chiba Y; Kinoshita M; Kijima N; Oji Y; Oka Y; Sugiyama H; Tsuboi A; Izumoto S; Kishima H; Hashimoto N
    Cancer Immunol Immunother; 2022 Jan; 71(1):189-201. PubMed ID: 34089373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.